Physician profile
Michael W Lamb
NPI 1790741767
$2,220.34
in general payments reported to CMS, 2019-2025
15 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $85.59 · 2021: $470 · 2022: $531 · 2023: $236 · 2024: $266 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $798.96 | 2019-2024 | Xelpros, Cequa, Bromsite |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $311.25 | 2019-2020 | |
| Rxsight INC | $267.86 | 2022-2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Coopervision INC. | $139.79 | 2021-2022 | |
| Glaukos Corporation | $138.05 | 2025 | Istent Infinite, Idosetr |
| Allergan, INC. | $133.96 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $108.37 | 2022 | |
| Optovue, INC. | $89.15 | 2019 | |
| Oyster Point Pharma, INC. | $65.08 | 2023-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $51.38 | 2024 | Infuse |
| Harrow Eye, LLC | $25.28 | 2025 | Vevye |
| Amgen INC. | $24.99 | 2024 | Tepezza |
| Aerie Pharmaceuticals, INC. | $24.88 | 2019 | |
| Alcon Vision LLC | $22.50 | 2025 | Tryptyr |
| Lkc Technologies, INC. | $18.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.